Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
THE ABC’S OF THE AHA/ACC Ischemic Heart Disease GUIDELINES Roger S. Blumenthal, MD Professor of Medicine Director, The Johns Hopkins Ciccarone Center For The Prevention of Heart Disease DEFINITION PRIMARY Prevention: Modification of risk factors or prevent their development to prevent or delay the onset of CHD. SECONDARY Prevention: Initiation of Rx to reduce recurrent CHD events in patients with CHD. PRIMARY AND A HALF Prevention*: As individuals with subclinical CHD are identified, the distinction between primary and secondary prevention becomes blurred. CHD=Coronary heart disease *Celermajer DS. JACC 2005;45:1994-6 ASPIRIN RECOMMENDATIONS SECONDARY PREVENTION I IIa IIb III Aspirin (75-325 mg daily) in those with known CHD or carotid artery or leg artery narrowings due to plaque. IIa IIb III Aspirin (100-325 mg daily) in those that have undergone CABG surgery*. A I B CABG=Coronary artery bypass graft, CHD=Coronary heart disease *To be administered within the first 48 hours after surgery in order to reduce the risk of saphenous vein graft failure. Doses >162 mg/day may be continued for up to one year. CLOPIDOGREL EVIDENCE: SECONDARY PREVENTION CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS (CURE) TRIAL RATE OF DEATH, MYOCARDIAL INFARCTION, OR STROKE 12,562 patients with a NSTE-ACS randomized to daily aspirin (75-325 mg) or clopidogrel (300 mg load, 75 mg thereafter) plus aspirin for 9 months ASPIRIN + CLOPIDOGREL ASPIRIN + PLACEBO P<0.001 0 3 6 9 MONTHS OF FOLLOW UP DAP=Dual antiplatelet therapy, NSTE-ACS=Non STsegment elevation acute coronary syndrome The CURE Trial Investigators. NEJM. 2001;345:494-502 12 ACE INHIBITOR RECOMMENDATIONS SECONDARY PREVENTION I IIa IIb III IIa IIb III A I B An ACE inhibitor in those following a MI, regardless of EF or in those with CAD* along with hypertension (SBP >120 mmHg), LVSD (EF <0.40), heart failure, DM, or CKD. Optional use of an ACE inhibitor in those with low risk CAD*, well controlled CV risk factors, a normal EF, and successful revascularization. ACE=Angiotensin converting enzyme, CAD=Coronary artery disease, CKD=Chronic kidney disease, CV=Cardiovascular, DM=Diabetes mellitus, EF=Ejection fraction, LVSD=Left ventricular systolic dysfunction, MI=Myocardial infarction, SBP=Systolic blood pressure *Defined by previous MI or angiographically significant CAD. ACE INHIBITOR EVIDENCE: SECONDARY PREVENTION HEART OUTCOMES PREVENTION AND EVALUATION (HOPE) STUDY CV DEATH, MI, OR STROKE (%) 9,297 patients with DM or vascular disease plus one additional CV risk factor, but without HF or known LVSD randomized to ramipril (10 mg) or placebo for 5 years 0.20 RAMIPRIL 0.15 PLACEBO 0.10 0.05 22% RRR, P<0.001 0.00 0 500 1000 DAYS OF FOLLOW-UP ACE-I reduce CV events in high-risk individuals ACE-I=Angiotensin converting enzyme inhibitors, DM=Diabetes mellitus, CV=Cardiovascular, HF=Heart failure, LVSD=Left ventricular systolic dysfunction, MI=Myocardial infarction HOPE Investigators. NEJM 2000;342:145-153 1500 PROBABILITY OF EVENT ACE INHIBITOR EVIDENCE: SECONDARY PREVENTION 0.4 SAVE AIRE TRACE Radionuclid e EF 40% Clinical and/or radiographic signs of HF Echocardiogram EF 35% Placebo 0.35 ACE-I 0.3 0.25 0.2 0.15 0.1 OR: 0.74 (0.66–0.83) 0.05 0 0 1 2 3 4 YEARS ACE-I provide substantial benefit in post-MI LVSD ACE-I=Angiotensin converting enzyme inhibitors, LVSD=Left ventricular systolic dysfunction, MI=Myocardial infarction, OR=Odds ratio Flather MD, et al. Lancet. 2000;355:1575–1581 BLOOD PRESSURE: LOWER IS BETTER Age at Risk (Y) 80-89 256 70-79 128 60-69 64 50-59 32 40-49 16 8 4 2 1 Ischemic Heart Disease Mortality Ischemic Heart Disease Mortality Ischemic Heart Disease Mortality 256 Age at Risk (Y) 80-89 128 70-79 64 60-69 32 50-59 16 40-49 0 8 4 2 1 0 120 140 160 180 Usual Systolic BP (mm Hg) BP=Blood pressure Prospective Studies Collaboration. Lancet. 2002;360:1903-1913 70 80 90 100 110 Usual Diastolic BP (mm Hg) BLOOD PRESSURE RECOMMENDATIONS SECONDARY PREVENTION I IIa IIb III Initiation or maintenance of lifestyle modification in those with a BP >120/80 mmHg. B I A IIa IIb III Use of an ACE inhibitor and/or b-blocker in those with a BP >140/90 mmHg*. Other drugs (i.e., thiazide diuretics) should be added in order to achieve the desired BP. ACE=Angiotensin converting enzyme, BP=Blood pressure, CKD=Chronic kidney disease, DM=Diabetes mellitus *A BP >130/80 mmHg should be used for individuals with CKD or DM BLOOD PRESSURE EVIDENCE: SECONDARY PREVENTION COMPARISON OF AMLODIPINE VS ENALAPRIL TO LIMIT OCCURRENCES OF THROMBOSIS (CAMELOT) TRIAL CV event rate* 1,991 patients with CAD and a DBP <100 mmHg randomized to amloidipine (10 mg), enalapril (20 mg), or placebo for 2 years 0.25 130/78 124/77 125/77 Placebo Enalapril Amlodipine 0.20 0.15 Follow-up BP (mmHg) 0.10 0.05 0 0 6 12 18 24 Months A BP <130/80 mmHg is associated with fewer CV events BP=Blood pressure, CAD=Coronary artery disease, CV=Cardiovascular, DBP=Diastolic blood pressure, HF=Heart failure, MI=Myocardial infarction, PAD=Peripheral arterial disease, TIA=Transient ischemic attack *Includes CV death, MI, cardiac arrest, coronary revascularization, hospitalization for HF or angina pectoris, stroke, TIA, development of PAD Nissen S et al. JAMA 2004;292:2217-26. b-BLOCKER RECOMMENDATIONS* SECONDARY PREVENTION A b-blocker in all patients following a MI. I IIa IIb III A I A beta-blocker in all patients with LVSD. IIa C IIb III A b-blocker in those with other forms of CV disease or DM, unless contraindicated. CV=Cardiovascular, DM=Diabetes mellitus, LVSD=Left ventricular systolic dysfunction, MI=Myocardial infarction *Relative contraindications include asthma, chronic obstructive pulmonary disease, insulin dependent diabetes mellitus, severe peripheral arterial disease, and a PR interval >0.24 seconds. CHOLESTEROL MANAGEMENT GUIDELINES SECONDARY PREVENTION I IIa IIb III B I Restriction of saturated fat (<7% of total calories) and cholesterol (<200 mg/day) in all patients. Promotion of daily physical activity and weight management in all patients. IIa IIb B III Increase in w-3 fatty acid consumption in all patients. LDL-C=Low density lipoprotein cholesterol CHOLESTEROL MANAGEMENT GUIDELINES (CONTINUED) SECONDARY PREVENTION I IIa IIb III IIa IIb III A I B Initiation or intensification of LDL-C lowering drug therapy in those with a baseline or on-treatment LDL-C level >100 mg/dl. Initiation of LDL-C lowering drug therapy in those with a baseline LDL-C level <100 mg/dl based on clinical judgment. LDL-C=Low density lipoprotein cholesterol CHOLESTEROL MANAGEMENT GUIDELINES (CONTINUED) GOALS As set forth by the Adult Treatment Panel III (ATP III) National Cholesterol Education Program (NCEP) RECOMMENDATIONS Obtain a fasting lipid profile in all patients. For those with a myocardial infarction, a fasting lipid profile should be obtained within 24 hrs of admission. Start therapeutic lifestyle changes in all patients, including: • Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg/day) • Addition of plant stanols/sterols (2 g/day) and viscous fiber (10-25 g/day) to enhance LDL-C lowering • Weight reduction • Increased physical activity Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486. ATP III LDL-C GOALS AND CUT-POINTS FOR DRUG THERAPY Risk Category LDL-C Goal High risk: CHD or CHD risk equivalents (10-year risk >20%) <100 mg/dL (optional goal: <70 mg/dL) Moderately high risk: 2+ risk factors* (10-year risk 10% to 20%) Moderate risk: 2+ risk factors* (10 year risk <10%) Lower risk: 0-1 risk factor* Initiate TLC Consider Drug Therapy 100 mg/dL >100 mg/dL (<100 mg/dL: consider drug options) <130 mg/dL (optional goal: <100 mg/dL) 130 mg/dL >130 mg/dL (100-129 mg/dL: consider drug options) <130 mg/dL 130 mg/dL >160 mg/dL 160 mg/dL >190 mg/dL (160-189 mg/dL: LDLlowering drug optional) <160 mg/dL *Risk factors for cardiovascular disease include: cigarettes smoking, hypertension (blood pressure >140/90 mmHg or on antihypertensive medication, HDL-C <40 mg/dl (>60 mg/dl is a negative risk factor), family history of premature CHD, age >45 years in men or >55 years in women. ATP=Adult Treatment Panel, CHD=Coronary heart disease, LDL-C=Low-density lipoprotein cholesterol, TLC=Therapeutic lifestyle changes Grundy, S. et al. Circulation 2004;110:227-39. PRIMARY THERAPIES TO LOWER LDL-C Class Drug(s) 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors [Statins] Atorvastatin (Lipitor) Fluvastatin (Lescol XL) Lovastatin (generic and Mevacor) Pravastatin (Pravachol) Rosuvastatin (Crestor) Simvastatin (Zocor) Bile acid sequestrants Cholestyramine (generic and Questran) Colesevelam (Welchol) Colestipol (Colestid) Cholesterol absorption inhibitor Ezetimibe (Zetia) Dietary Adjuncts Soluble fiber Soy protein Stanol esters HMG-COA REDUCTASE INHIBITOR: SECONDARY PREVENTION PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY (PROVE-IT)—TIMI 22 STUDY 4,162 patients with an ACS randomized to atorvastatin (80 mg) or pravastatin (40 mg) for 24 months Recurrent MI or Cardiac Death 30 Atorvastatin Pravastatin 25 16% RRR 20 15 10 5 P =0.005 0 3 6 9 12 15 18 21 24 27 30 Follow-up (months) Acute intensive therapy significantly reduces the event rate ACS=Acute coronary syndrome, CV=Cardiovascular, MI=Myocardial infarction, RRR=Relative risk reduction Cannon CP et al. NEJM 2004;350:1495-1504 HMG-COA REDUCTASE INHIBITOR: SECONDARY PREVENTION SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S) 4,444 patients with angina pectoris or previous MI randomized to simvastatin (20-40 mg) or placebo for 5.4 years 30% RRR 11.5 Mortality (%) 12 8.2 8 4 P<0.001 0 Placebo Simvastatin Statins provide significant benefit in those with average LDL-C levels MI=Myocardial infarction, RRR=Relative risk reduction 4S Group. Lancet 1994;344:1383–1389 HMG-COA REDUCTASE INHIBITOR: SECONDARY PREVENTION HEART PROTECTION STUDY (HPS) 20,536 patients with CAD, other occlusive arterial disease, or DM randomized to simvastatin (40 mg) or placebo for 5.5 years Event Rate Ratio (95% CI) Baseline LDL-C (mg/dL) Statin (n = 10,269) Placebo (n = 10,267) <100 282 (16.4%) 358 (21.0%) 100–129 668 (18.9%) 871 (24.7%) 130 1083 (21.6%) 1356 (26.9%) All patients 2033 (19.8%) 2585 (25.2%) Statin Better Statin Worse 0.76 (0.72–0.81) P<0.0001 0.4 0.6 0.8 1.0 1.2 1.4 Statins provide significant benefit across a broad range of LDL-C levels CAD=Coronary artery disease, CI=Confidence interval, DM=Diabetes mellitus, HPS Collaborative Group. Lancet 2002;360:7-22 CIGARETTE SMOKING CESSATION GUIDELINES GOALS Complete cessation No environmental tobacco smoke exposure I B IIa IIb III RECOMMENDATIONS Ask about tobacco use at every visit. In a clear, strong, and personalized manner, advise the patient to stop smoking. Urge avoidance of exposure to secondhand smoke at work and home. Assess the patient’s willingness to quit smoking. Develop a plan for smoking cessation and arrange follow-up. Provide counseling, pharmacologic therapy, and referral to formal smoking cessation programs as indicated. SMOKING CESSATION PHARMACOTHERAPY* Side Effects Dosage Duration Instructions Seizure disorder Eating disorder Taking MAO inhibitor Pregnancy Insomnia Dry mouth 150 mg QAM then 150 mg BID 3 days Start 1-2 weeks before quit date. Take second dose in early afternoon or decrease to 150 mg QAM for insomnia. Within 2 weeks of a MI Unstable angina Arrhythmias Decompensated heart failure Skin reaction Insomnia 21 mg QAM 14 mg QAM 7 mg QAM or 15 mg QAM Agent Caution Bupropion SR (Zyban®) Transdermal Nicotine Patch** Maintenance (8 weeks, but may be used up to 6 months) 4 weeks 2 weeks 2 weeks 8 weeks *Pharmacotherapy combined with behavioral support provides the best success rate **Other nicotine replacement therapy options include: nicotine gum, lozenge, inhaler, nasal spray Apply to different hairless site daily. Remove before bed for insomnia. Start at <15 mg for <10 cigs/day SMOKING CESSATION PHARMACOTHERAPY: VARENICLINE Study 1 p<0.001 for V vs B p<0.001 for V vs P Two trials compared treatment with varenicline, a nicotine acetylcholine receptor agonist, to treatment with buproprion or placebo. Study 2 p<0.001 for V vs B p<0.001 for V vs P These trials included a total of almost 700 participants. The mean duration of smoking was 25 years. Varenicline yielded higher rates of smoking cessation than buproprion or placebo. JAMA 2006:296:47-55 and JAMA 2006;296:56-63 WEIGHT MANAGEMENT GUIDELINES GOALS RECOMMENDATIONS Calculate BMI* and measure waist circumference as part of evaluation. Monitor response of BMI and waist circumference to therapy. BMI 18.5 to 24.9 kg/m2 Women: <35 inches Men: <40 inches 10% weight reduction within the first year of therapy I IIa IIb III B I A IIa IIb III Start weight management and physical activity as appropriate. If BMI and/or waist circumference is above goal, initiate caloric restriction, measures to increase caloric expenditure, and treatment strategies for the metabolic syndrome. BMI=Body mass index *BMI is calculated as the weight in kilograms divided by the body surface area in meters2. Overweight state is defined by BMI=25-30 kg/m2. Obesity is defined by a BMI >30 kg/m2. PREVALENCE OF OBESITY IN U.S. ADULTS 1996 1991 2003 % State Population No Data Source: CDC Overweight and Obesity <10% 10%–14% 15%–19% 20%–24% ≥ 25% CV RISK INCREASES WITH BODY MASS INDEX Hazard Ratio Hemorrhagic Stroke Ischemic Stroke Ischemic Heart Disease 4.0 4.0 4.0 2.0 2.0 2.0 1.0 1.0 1.0 0.5 0.5 0.5 16 20 24 28 32 36 16 20 24 28 32 36 Body Mass Index (kg/m2)* CV=Cardiovascular Body mass index is calculated as the weight in kilograms divided by the body surface area in meters2. Mhurchu N et al. Int J Epidemiol 2004;33:751-758 16 20 24 28 32 36 DIABETES MELLITUS GUIDELINES GOALS Goal HbA1C <7% RECOMMENDATIONS Intensive lifestyle modification to prevent the development of DM (especially in those with the metabolic syndrome) Aggressive management of CV risk factors (i.e., tobacco use, hypertension, dyslipidemia, physical inactivity, and overweight and obese states) I IIa IIb III Hypoglycemic therapy to achieve normal to near normal fasting plasma glucose as defined by the HbA1C (<7%) • Weight reduction and exercise • Oral hypoglycemic agents • Insulin therapy B I C IIa IIb III Coordination of diabetic care with the patient’s primary physician and/or endocrinologist. CV=Cardiovascular, DM=Diabetes mellitus, HbA1C=Glycosylated hemoglobin EXERCISE GUIDELINES GOALS RECOMMENDATIONS Minimum: 30 minutes, 5 days per week Optimal: 30 minutes daily I B IIa IIb III Assess risk, preferably with exercise test, to guide prescription. Encourage aerobic activity (e.g., walking, jogging, cycling) supplemented by an increase in daily activities (e.g., walking breaks at work, gardening, household work). Encourage resistance training (e.g., weight machines, free weights) 2 days a week (Class IIb, Level C) Encourage cardiac rehabilitation for patients with chronic stable angina, recent myocardial infarction, left ventricular systolic dysfunction, or recent coronary artery bypass graft surgery. EJECTION FRACTION GUIDELINES SECONDARY PREVENTION Echocardiography in those following a STEMI to reevaluate ventricular function when results are used to guide therapy*. I IIa B IIb III Echocardiography or radionuclide angiography in those following a NSTE-ACS when results are used to guide therapy*. NSTE-ACS=Non-ST-segment elevation acute coronary syndrome, STEMI=STsegment elevation myocardial infarction *Includes use of an aldosterone antagonist, digitalis, and/or an implantable cardioverter defibrillator RELATIONSHIP BETWEEN EF* AND MORTALITY Cardiac Mortality % 50 <30 40 30 31-35 20 36-45 10 46-53 0 20 30 40 50 54-60 60 Ejection Fraction (%) EF=Ejection fraction *Post myocardial infarction Brodie B et al. Am J Cardiol 1992;69:1113 >60 70 80 ALDOSTERONE ANTAGONIST: SECONDARY PREVENTION EPLERENONE POCT-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY (EPHESUS) All Cause Mortality (%) 3,313 patients with evidence of heart failure and LVSD (EF <0.40) after a MI randomized to eplerenone (50 mg) or placebo for 16 months Eplerenone Placebo 25 20 15 10 5 0 RR = 0.85, P=0.008 0 6 12 18 24 30 36 Month Aldosterone inhibition provides significant benefit in patients with post-MI heart failure and LVSD EF=Ejection fraction, LVSD=Left ventricular systolic dysfunction, MI=Myocardial infarction Pitt B et al. NEJM 2003;348:1309-21 ICD ALGORITHM AT LEAST ONE MONTH FOLLOWING A MYOCARDIAL INFARCTION EF < 30% EF > 40% EF 31-40% Additional Marker of Electrical Instability? Yes + No EPS EF=Ejection fraction, EPS=Electrophysiology study, ICD=Implantable cardioverter defibrillator, Rx=Treatment, SCD=Sudden cardiac death, NEJM 349:1836,2003 – No ICD. Medical Rx % Mortality Reduction w/ ICD Rx ICD: SECONDARY PREVENTION* Overall death 75% 73% 61% 55% 54% 31% 1 27 Months EF <35% *Primary prevention of sudden cardiac death 1 Moss AJ. N Engl J Med. 1996;335:1933-1940 Buxton AE. N Engl J Med. 1999;341:1882-1890 3 Moss AF. N Engl J Med. 2002;346:877-883 2 Arrhythmic death 2 39 Months EF <40% 3 20 Months EF <30% PREVENTION PYRAMID Secondary Primary Primordial ASA ACE-I Rehab β-blockers +Primary Lipids Hypertension Smoking cessation Diabetes +Primordial Physical activity Healthy eating Ideal weight Psychosocial factors Familial predisposition ACE-1 = angiotensin converting enzyme inhibitor; ASA = aspirin